Volume 8, Issue 4 (Autumn 2022)                   Caspian.J.Neurol.Sci 2022, 8(4): 197-205 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Balali P, Marashi S S, Agah E, Shafiee Sabet M, Rahimian N, Shafiee S et al . Safety and Efficacy of Memantine in Improving Cognitive Function of Patients with Epilepsy. Caspian.J.Neurol.Sci 2022; 8 (4) :197-205
URL: http://cjns.gums.ac.ir/article-1-562-en.html
1- Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2- Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Family Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4- Department of Neurosurgery, Faculty of Medicine, Mazandaran University of Medical Sciences
Abstract:   (379 Views)
Background: The prevalence of cognitive impairment among patients with epilepsy is about 70%.
There is still no approved medication for the treatment of this problem.
Objectives: The present study aims to assess the safety and efficacy of memantine in improving the
cognitive function of patients with epilepsy.
Materials & Methods: This is a pilot, randomized, double-blind, placebo-controlled, parallelgroup
clinical trial, conducted in a hospital in Tehran, Iran during 2018-2019. Participants were
randomly allocated to receive memantine (5 mg/day in the first eight weeks and 10 mg/day in
the second eight weeks) or placebo in a 1:1 ratio. Participants underwent the Mini-mental State
Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Frontal Assessment Battery
(FAB) before and after the intervention. The primary and secondary measures were safety and
change in the cognitive test scores, respectively.
Results: Out of 53 allocated participants, 33 completed the study. Drug intolerance including
headache, somnolence, and dizziness was not significantly different between the two groups. The
Intention-to-Treat analyses demonstrated no significant change in MoCA and FAB scores between
the two groups after the intervention, but a significant improvement in the MMSE score of the
memantine group (P=0.047) was observed. After controlling confounding factors, there was no
significant difference in scores of any cognitive tests between the two groups.
Conclusion: Memantine is a safe drug for patients with epilepsy, but it may not exert a beneficial
effect on the cognitive function of these patients.
Full-Text [PDF 1409 kb]   (109 Downloads) |   |   Full-Text (HTML)  (44 Views)  
Type of Study: Research | Subject: Special
Received: 2022/09/14 | Accepted: 2022/09/28 | Published: 2022/09/28

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Caspian Journal of Neurological Sciences

Designed & Developed by : Yektaweb